{"product_id":"glp-3rt-oral","title":"GLP-3RT Oral Spray","description":"\u003ch3\u003eGLP-3RT — oral format\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003e15mL Oral Spray\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eThis listing supplies the compound in an orally administered format rather than a lyophilized vial requiring reconstitution. Oral and sublingual routes are studied for peptides because they remove injection handling from the workflow, while raising well-documented questions about gastrointestinal stability and absorption that vary by compound and formulation. The research summarised below was generated across multiple routes; the reported-amounts table records the route for each figure. Nothing here claims equivalence between routes.\u003c\/p\u003e\u003cp\u003eBecause this oral format is supplied pre-prepared, the reconstitution arithmetic that applies to our lyophilized GLP-3RT vials does not apply here: there is no diluent volume to choose and no concentration to derive. Store as labelled on the product, and consult the lot-matched Certificate of Analysis for the material you receive rather than generalising from a different format of the same compound.\u003c\/p\u003e\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003e\u003cem\u003eIncretin-pathway triple agonist (GIP \/ GLP-1 \/ glucagon receptor)\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eGLP-3RT (LY3437943) is an investigational peptide agonist engineered to activate three receptors in the incretin\/glucagon family: GIP, GLP-1, and glucagon receptors. It has been evaluated in company-sponsored clinical trials, including a prominent phase 2 obesity study published in the New England Journal of Medicine and earlier multiple-ascending-dose work in type 2 diabetes.\u003c\/p\u003e\u003cp\u003eResearchers focus on GLP-3RT because dual and triple agonists extend the pharmacology already established for GLP-1 receptor agonists. In the phase 2 obesity trial, once-weekly subcutaneous escalation regimens produced substantial, dose-dependent mean body-weight reductions over 48 weeks compared with placebo, alongside metabolic marker changes typical of this class. Gastrointestinal adverse events were the most frequently discussed tolerability theme, consistent with incretin mimetics.\u003c\/p\u003e\u003cp\u003eEducational dosage content should cite trial arms and titration schedules as documented research protocols. GLP-3RT remains investigational for the indications studied in those papers and is not framed here as consumer guidance. Research-use discussions of vial sizes outside formal trials must stay clearly separated from labeled clinical development doses.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003cp\u003eGLP-3RT simultaneously engages GIP receptor, GLP-1 receptor, and glucagon receptor pathways. GLP-1 receptor activation is associated with enhanced glucose-dependent insulin secretion, slowed gastric emptying, and central appetite signaling. GIP receptor activity adds another incretin axis that may support insulinotropic and adipose-tissue effects in combination regimens. Glucagon receptor engagement is explored for energy-expenditure and hepatic lipid-metabolism contributions. The triple design aims to combine reduced energy intake with metabolic effects not fully captured by GLP-1 agonism alone.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eobesity clinical research\u003c\/li\u003e\n\u003cli\u003etype 2 diabetes\u003c\/li\u003e\n\u003cli\u003eincretin pharmacology\u003c\/li\u003e\n\u003cli\u003ebody-weight regulation\u003c\/li\u003e\n\u003cli\u003ecardiometabolic markers\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eEndocrinology and obesity-medicine trialists, metabolic pharmacologists, and translational teams comparing multi-receptor agonists with GLP-1 S- or GLP-2T-class agents. Academic groups analyze body-composition and liver-fat secondary endpoints. This audience is clinical-research oriented rather than cosmetic or injury-repair focused.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e1 mg – 12 mg\u003c\/td\u003e\n\u003ctd\u003eonce weekly\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003ePhase 2 obesity trial maintenance dose arms (Jastreboff et al., NEJM 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e500 mcg – 12 mg\u003c\/td\u003e\n\u003ctd\u003eonce weekly (study-defined)\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003ePhase 1b multiple-ascending-dose work in type 2 diabetes (LY3437943)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003cp\u003eFollow manufacturer or trial pharmacy instructions for investigational product. Research lyophilizates are typically kept refrigerated, protected from light; reconstituted multi-dose research vials are refrigerated and timed to supplier stability limits. Do not freeze reconstituted solutions unless a COA explicitly allows it.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003cp\u003eFormal trials study GLP-3RT as monotherapy against placebo or active comparators, not as part of informal peptide stacks. Combining with other incretin agents would duplicate pathway stimulation and is outside evidence-based research design. Lifestyle and background diabetes medications in trials are protocol-defined, not ad-hoc stacks.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e≥99.0% by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFormat\u003c\/th\u003e\n\u003ctd\u003e15mL Oral Spray\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eSee product format\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eThird-party laboratory\u003c\/th\u003e\n\u003ctd\u003eAxisPharm, LLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLots with COA on file\u003c\/th\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003eLY3437943, triple agonist, GGG tri-agonist\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eEngineered for once-weekly administration in clinical development (long-acting incretin-class peptide kinetics)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWhat is the dosage for GLP-3RT?\u003c\/strong\u003e\u003cbr\u003eIn the landmark phase 2 obesity trial, participants received once-weekly subcutaneous GLP-3RT with maintenance doses of 1 mg, 4 mg, 8 mg, or 12 mg after escalation at higher strengths. Those figures are documented clinical-research arms, not a consumer recommendation. Always cite the primary NEJM protocol when discussing dose.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow much bac water for GLP-3RT?\u003c\/strong\u003e\u003cbr\u003eTrial product is pharmacy-prepared; research vials sold as lyophilized powder require label-specific diluent volumes. Choose a diluent volume that makes weekly mg doses easy to measure on an insulin syringe (for example, concentrating so that 0.1-0.5 mL matches the intended mg). Calculate from vial_mg \/ mL.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eGLP-3RT dosage per day\u003c\/strong\u003e\u003cbr\u003eClinical development uses weekly—not daily—dosing. Dividing a weekly mg amount into daily micro-doses is not how the phase 2 obesity protocol was written. Educational charts should show mg per week and titration steps.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eGLP-3RT dosage chart\u003c\/strong\u003e\u003cbr\u003eA literature-faithful chart lists escalation steps toward 4, 8, or 12 mg weekly maintenance, including the lower 1 mg arm. Higher-dose groups in phase 2 used gradual increases every four weeks to improve gastrointestinal tolerability. Reproduce numbers from the peer-reviewed methods section.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow long does GLP-3RT take?\u003c\/strong\u003e\u003cbr\u003eIn the 48-week phase 2 obesity study, mean weight-change curves separated over months, with large effects reported by week 48 at higher doses. Early gastrointestinal symptoms, when they occur in incretin trials, often appear during escalation. Timelines are trial endpoints, not guarantees for any individual.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eWhat is the half life of GLP-3RT?\u003c\/strong\u003e\u003cbr\u003eGLP-3RT was designed as a long-acting molecule compatible with once-weekly subcutaneous dosing. Exact terminal half-life values should be taken from clinical pharmacology sections of sponsor publications rather than informal blogs.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eCan GLP-3RT be stacked with other peptides?\u003c\/strong\u003e\u003cbr\u003ePivotal studies evaluate it alone within controlled backgrounds. Stacking with other GLP-1 or GIP agents is not an evidence-based research protocol and may compound mechanism-overlapping effects. Educational sites should discourage casual polypharmacy framing.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow is GLP-3RT dosage calculated from a research vial?\u003c\/strong\u003e\u003cbr\u003emg_dose = concentration_mg_per_mL x mL_drawn. If a 20 mg vial is reconstituted with 2 mL, concentration is 10 mg\/mL, so 0.4 mL provides 4 mg. Use a calculator and dual-check units before any research preparation.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37366315\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eTriple-Hormone-Receptor Agonist GLP-3RT for Obesity - A Phase 2 Trial.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36354040\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eLY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37385280\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eGLP-3RT, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","brand":"US Peptide Labs","offers":[{"title":"20mg","offer_id":44076219662423,"sku":"CW\/P-RET20O","price":220.0,"currency_code":"USD","in_stock":true},{"title":"40mg","offer_id":44076811878487,"sku":"CW\/P-RET40O","price":350.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/glp-3rt-oral-20mg.png?v=1790198576","url":"https:\/\/uspeptidelabs.co\/products\/glp-3rt-oral","provider":"US Peptide Labs | High Quality American-made","version":"1.0","type":"link"}